Skip to content

Author

A. Aguirre

We have 3 of 48 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract PR008: EMT-associated focal adhesion signaling mediates resistance to RAS inhibition

Direct inhibition of oncogenic RAS has emerged as a clinically active therapeutic strategy for RAS-addicted cancers, including pancreatic ductal adenocarcinoma (PDAC). However, resistance is likely to limit the durability of therapeutic response, motivating combination strategies that target adaptive survival mechani...

Joshua H. Choe, Kyle J. Seamon, Julien Dilly et al. · 0 citations
Sep 2026

Abstract A140: Patient-derived organoids and precision medicine: Insights from the PASS-01 clinical trial in PDAC

Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage with limited treatment options. Patient-derived organoids (PDOs) can model tumors, identify determinants of therapeutic response, and support precision medicine. In the multi-institutional PASS-01 trial of metastatic PDAC, biopsies f...

A. Habowski, Fatim M. Kouassi, James A. Rouse et al. · 0 citations
Sep 2026

Abstract A041: KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer

These studies establish a comprehensive proteomic resource for the PDAC/KRASi research community and identify ALPP/ALPPL2 as a promising cell surface target for combination with KRASi to drive deeper, sustained responses and prevent or forestall KRASi resistance.

Jonathan M. DeLiberty, Fan-Yi Kong, Qi-Jia Yu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.